PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
19.35%
Revenue growth above 1.5x AVGO's 6.32%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
14.31%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
22.75%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
22.75%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
22.78%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
19.05%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
21.62%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.64%
Share count expansion well above AVGO's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.39%
Diluted share count expanding well above AVGO's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
1601.67%
OCF growth above 1.5x AVGO's 9.32%. David Dodd would confirm a clear edge in underlying cash generation.
8479.93%
FCF growth above 1.5x AVGO's 9.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
465.05%
10Y revenue/share CAGR 1.25-1.5x AVGO's 416.86%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
81.02%
5Y revenue/share CAGR at 50-75% of AVGO's 134.28%. Martin Whitman would worry about a lagging mid-term growth trajectory.
54.70%
3Y revenue/share CAGR at 75-90% of AVGO's 62.33%. Bill Ackman would expect new product strategies to close the gap.
1740.46%
10Y OCF/share CAGR above 1.5x AVGO's 580.47%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
1114.11%
5Y OCF/share CAGR above 1.5x AVGO's 92.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
3177.45%
3Y OCF/share CAGR above 1.5x AVGO's 39.51%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
571.17%
Net income/share CAGR at 50-75% of AVGO's 869.72%. Martin Whitman might question if the firm’s product or cost base lags behind.
94.79%
Below 50% of AVGO's 414.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
1435.61%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1152.88%
10Y equity/share CAGR 1.25-1.5x AVGO's 862.23%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
146.87%
5Y equity/share CAGR at 75-90% of AVGO's 165.61%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
67.51%
Below 50% of AVGO's 201.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.43%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-1.35%
Inventory is declining while AVGO stands at 8.08%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
15.90%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
10.85%
BV/share growth above 1.5x AVGO's 5.15%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
10.59%
R&D growth drastically higher vs. AVGO's 13.26%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
9.47%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.